New and updated preclinical and clinical data presented by biopharma firms at the American Society of Clinical Oncology annual meeting, including: Akeso, Alphamab Oncology, Amgen, Ascentage, Astrazeneca, Bristol Myers Squibb, Carsgen, Cstone, Daiichi Sankyo, Eisai, Henlius, Immutep, Innovent Biologics, Jacobio, JW, Kyowa Kirin, MEI, Oricell, Takeda.
Shanghai Henlius Biotech Inc. signed an exclusive licensing deal with Organon LLC under which Organon will in-license rights for two of Henlius’ internally developed biosimilar candidates for global commercialization, excluding China, Hong Kong, Macau and Taiwan.
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Eisai, Foresee, Hutchmed, Iaso, Innovent Biologics, J Ints Bio, Mezzion, Revive, Takeda, United.
Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: Ampio, Athersys, Biovaxys Technology, Cocrystal, GSK, Tetra Bio-Pharma Australia, Immedica, Moderna, Orphanpacific, Pfizer, Scineuro, Takeda, Transcenta, Vaxart.
Abliva AB has gone above its market capitalization to raise the money it needs to start a phase II/III trial of KL-1333 for the treatment of primary mitochondrial disease.
Although the death toll in the U.S. is nearing 1 million lives lost, signs continue to suggest that an end is in sight for the COVID-19 pandemic, the most disruptive global health crisis in a century.
RSS
